相关实验视频

Updated: Jun 13, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

低酸血症纠正减少了ICANS发生率和持续时间在CAR T细胞疗法:一个聚合的临床试验分析分析

Jack Pengfei Tang¹, Penelope Lafeuille², Alexandru Socolov²

¹Division of Pediatric Hematology-Oncology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California.

Cancer research communications

|September 13, 2024

概括

低度血症与CAR T细胞治疗中的免疫效应细胞相关神经毒性综合征 (ICANS) 有关. 补充可能会减少ICANS的发生率和持续时间,提供潜在的生物标志物和干预措施.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
神经学神经学

背景情况:

化学抗原受体 (CAR) T细胞疗法是一种有前途的癌症治疗方法.
免疫效应细胞相关神经毒性综合征 (ICANS) 是CAR T细胞治疗的严重并发症.
目前ICANS的治疗方法有限,这凸显了对新型干预措施的需求.

研究的目的:

调查电解质失调,特别是低血,以及在接受CAR T细胞治疗的患者中ICANS的发生率和严重程度之间的关联.
评估补充对ICANS结果的影响.

主要方法:

对499名接受针对CD19的CAR T细胞治疗的患者进行了回顾性审查.
临床毒性,血清电解质数据和ICANS发病率,严重程度和持续时间的分析.
低血和补充与ICANS事件的相关性.

主要成果:

低血症在CAR T细胞接受者中很常见,并且是唯一与较高ICANS发病率显著相关的电解质障碍.
低酸盐血症患者的补充与ICANS发病率和持续时间的降低相关.
低酸血症与脑病变有独特的联系,并且与ICANS和细胞因子释放综合征严重程度有很强的相关性.

结论:

血清可以作为可靠的生物标志物,用于预测CAR T细胞治疗中的ICANS风险.
快速,有目标的补充可能是一个安全有效的干预措施,以减轻ICANS.
这一发现提供了一种潜在的低成本策略,用于提高CAR T细胞治疗期间的患者安全.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.